Replimune Group’s (REPL) “Buy” Rating Reaffirmed at HC Wainwright

Replimune Group (NASDAQ:REPL)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 61.44% from the stock’s previous close.

REPL has been the topic of several other reports. Roth Mkm initiated coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Wedbush restated an “outperform” rating and issued a $16.00 price target on shares of Replimune Group in a report on Thursday, June 6th. Finally, Barclays lifted their price objective on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $16.20.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $10.53 on Tuesday. Replimune Group has a 52 week low of $4.92 and a 52 week high of $20.05. The company has a 50-day moving average price of $9.89 and a 200 day moving average price of $8.28. The company has a market cap of $719.41 million, a P/E ratio of -3.25 and a beta of 1.22. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.10. Research analysts predict that Replimune Group will post -3.13 earnings per share for the current year.

Insider Activity

In related news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Replimune Group

Large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC purchased a new position in Replimune Group in the 1st quarter valued at about $927,000. BNP Paribas Financial Markets grew its stake in Replimune Group by 517.9% in the 4th quarter. BNP Paribas Financial Markets now owns 196,251 shares of the company’s stock worth $1,654,000 after acquiring an additional 164,490 shares during the period. Clearbridge Investments LLC acquired a new position in Replimune Group in the 4th quarter valued at $2,282,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Replimune Group during the 1st quarter worth $1,088,000. Finally, Rafferty Asset Management LLC boosted its holdings in shares of Replimune Group by 148.1% during the fourth quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock worth $3,906,000 after purchasing an additional 276,596 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.